BMI – Ayurved Healing

Triphala for Weight Management: Clinical Trial Evidence on Fat Reduction

Dr. Meera Iyer — Sat, 07 Mar 2026 10:28:54 +0000

Triphala is often presented as a supplement for bowel regularity, but its Ayurvedic identity is broader and more specific than the modern label “gentle laxative.” The official formulation is a powder prepared from three fruit pericarps: Haritaki (Terminalia chebula Retz.), Bibhitaka (Terminalia bellirica (Gaertn.) Roxb.), and Amalaki (Phyllanthus emblica L., also known as Emblica officinalis Gaertn.). The Ayurvedic Formulary of India describes these ingredients in equal proportions.

Modern clinical literature has also examined Triphala-related preparations for body weight, waist circumference, blood lipids, and glucose regulation. Several short-term trials report favorable changes, but the studies differ greatly in formulation, dose, participant characteristics, co-interventions, and methodological quality. Triphala is therefore best regarded as a possible adjunct within a supervised weight-management plan rather than as a stand-alone fat-loss treatment.

Triphala in the Ayurvedic Formulary

Official Ayurvedic references list Triphala Churna as a combination of equal parts Haritaki, Bibhitaka, and Amalaki fruit-pericarp powders. Government-linked Ayurvedic resources give a reference dose of 3–6 grams of the churna and list warm water, honey, or ghee among possible anupanas, depending on the therapeutic context and the patient. These are general formulary directions, not a universal prescription for obesity.

Ayurvedic Standard Treatment Guidelines include Triphala Churna among the medicines that may be selected in the management of Sthaulya, together with dietary regulation, physical activity, assessment of associated conditions, and individualized treatment. The guidelines do not present Triphala as a rapid “fat burner.” Classical Ayurvedic prescribing considers digestive state, bowel pattern, strength, constitution, associated disorders, season, formulation, dose, and anupana before selecting a medicine.

The 2012 Itrifal Saghir Trial

A frequently cited human trial was published in 2012 in the DARU Journal of Pharmaceutical Sciences, not in Alternative Therapies in Health and Medicine. It was conducted in Iran and evaluated Itrifal Saghir, a Traditional Iranian medicine containing equal parts of the same three fruits used in Triphala. The preparation also involved honey and almond oil, so its findings should not automatically be applied to every Triphala powder, tablet, capsule, or extract.

The randomized, double-blind, placebo-controlled trial enrolled 62 people with simple obesity. Participants were assigned to 5 grams of Itrifal Saghir or placebo twice daily for 12 weeks. Thirty-one participants were allocated to each group. The article reported the following differences in favor of the active preparation:

Outcome	Reported difference versus placebo	95% confidence interval	Statistical result
Body weight	4.82 kg greater reduction	3.52–6.11 kg	p<0.001
Waist circumference	4.01 cm greater reduction	2.13–5.90 cm	p<0.001
Hip circumference	3.21 cm greater reduction	1.96–4.45 cm	p<0.001

No adverse effects or significant changes in the measured liver and kidney function tests were reported during the trial. Nevertheless, the study was small, lasted only 12 weeks, and evaluated a particular Itrifal Saghir preparation at 10 grams daily. It did not establish long-term weight maintenance, cardiovascular benefit, or the effectiveness of lower-dose commercial Triphala products.

What the Clinical Evidence Syntheses Found

A 2022 meta-analysis combined seven randomized trials involving 458 participants. In the pooled analysis, Triphala-containing interventions were associated with reductions in body weight, body mass index, and waist circumference. The estimated reductions were 2.99 kilograms for body weight, 0.79 kg/m² for BMI, and 1.86 centimetres for waist circumference.

The results varied substantially from study to study. Statistical heterogeneity was 94.4% for body weight, 90.4% for BMI, and 88.8% for waist circumference. Such high heterogeneity means the pooled averages should not be interpreted as a predictable result for an individual. The included trials used widely differing doses and preparations, and some assessed Triphala with other therapies rather than as an isolated intervention.

A broader systematic review and meta-analysis published in 2025 included 15 controlled studies of Triphala or Triphala Guggul, comprising 800 participants. A pooled analysis of five studies using oral Triphala found a mean body-weight difference of −2.4 kilograms compared with controls. Heterogeneity remained high at 91%, and the pooled effect on BMI was not statistically significant.

Evidence source	Participants	Main finding	Important qualification
2012 Itrifal Saghir RCT	62	Greater reductions in weight, waist, and hip measurements	Single short-term trial of a specific related formulation
2022 meta-analysis	458 across 7 trials	Pooled reductions in weight, BMI, and waist circumference	Very high between-study heterogeneity
2025 systematic review and meta-analysis	800 across 15 studies	Oral Triphala subgroup showed a modest weight reduction	BMI result was inconclusive and study quality varied

Together, these findings support a possible short-term effect on anthropometric measurements, particularly body weight and waist circumference. They do not define an optimal preparation, establish a dependable dose-response relationship, or demonstrate that weight reduction persists after treatment ends.

Lipids and Glucose: A Mixed Clinical Picture

A 2021 systematic review examined 12 human studies with a combined 749 participants. Six studies reported reductions in one or more lipid measurements, including total cholesterol, LDL cholesterol, or triglycerides. The review also identified reductions in fasting glucose among some participants with diabetes, whereas comparable glucose changes were not established in participants without diabetes.

The studies were too diverse to justify a precise expectation such as a fixed LDL or triglyceride reduction from a standard daily dose. They included different populations, treatment durations, Triphala doses, extracts, powders, and mixed-herbal interventions. The findings therefore cannot be treated as equivalent to the established effects of prescribed lipid-lowering or glucose-lowering medicines.

A placebo-controlled, double-blind trial involving 90 adults with hypercholesterolaemia illustrates this uncertainty. Participants received a combination of Guggulu and Triphala or placebo three times daily for three months. LDL cholesterol declined in both groups, but the herbal combination was not superior to placebo for total cholesterol, LDL cholesterol, BMI, or waist circumference. Two participants receiving the herbal preparation developed a hypersensitivity rash.

Triphala should not be used to replace statins, diabetes medicines, nutritional therapy, or medical evaluation. People with elevated cholesterol or glucose require appropriate testing and individualized management of their overall cardiovascular and metabolic risk.

Plausible Mechanisms Under Investigation

Laboratory and pilot human studies have explored several biological pathways that may help explain the anthropometric findings. These experiments are useful for generating hypotheses, but they do not prove that a particular pathway causes clinically meaningful weight loss in humans.

Gut Microbiota

A four-week randomized, double-blind pilot trial assigned 31 healthy adults to Triphala, Manjistha, or placebo. Participants were instructed to take 2,000 milligrams daily. Microbiome analysis was completed in 29 participants, including nine in the Triphala group.

Microbial responses were highly personalized, and no bacterial taxon changed uniformly in everyone taking Triphala. The herb-treated groups showed trends toward a lower Firmicutes-to-Bacteroidetes ratio and a greater relative abundance of Akkermansia muciniphila, along with reductions in some Rikenellaceae. Because this was a small study of healthy adults and did not test weight loss, the observed microbiome changes cannot be interpreted as proof of an anti-obesity action.

Adipocyte Differentiation

An in-vitro study using 3T3-L1 cells found that an aqueous Triphala extract reduced intracellular lipid accumulation in a concentration-dependent manner. It also reduced the expression of several genes involved in adipocyte differentiation and lipid metabolism, including PPAR-γ, C/EBP-α, fatty-acid synthase, and GLUT4.

This experiment demonstrates activity in a laboratory cell model. The concentrations applied directly to cultured cells do not establish an effective oral human dose, and inhibition of adipogenesis in vitro does not by itself demonstrate loss of established body fat in people.

Animal Metabolism and Digestive Enzymes

In a 10-week mouse model of diet-induced obesity, Triphala and its individual fruit constituents were associated with reductions in body weight, body fat, energy intake, and several lipid measurements. Animal models help identify possible metabolic actions, but their results cannot be transferred directly to human treatment recommendations.

A 2025 laboratory investigation also found pancreatic-lipase inhibitory activity in hydroethanolic Triphala extracts and fractions. This provides a possible digestive-enzyme mechanism for further study. The experiment did not demonstrate a clinically important reduction in human fat absorption, and it does not make Triphala equivalent to the prescription lipase inhibitor orlistat.

Formulation and Dose Matter

“Triphala” can refer to traditional churna, tablets containing powdered fruits, concentrated extracts, proprietary capsules, Itrifal preparations, or products combined with Guggulu and other herbs. Ten grams of a whole-fruit preparation cannot be assumed to equal 10 grams of an extract, and milligram amounts from one standardized product cannot be directly converted into a dose of another.

The official reference dose of 3–6 grams for Triphala Churna should be interpreted within Ayurvedic clinical practice. The 2012 obesity trial used 10 grams daily of Itrifal Saghir, the human microbiome pilot used 2 grams daily, and a small safety study administered 2.5 grams daily of aqueous extract to 20 healthy volunteers for four weeks. These studies do not establish that higher doses are more effective or appropriate for unsupervised long-term use.

No reliable clinical comparison establishes that Triphala powder has greater bioavailability or weight-loss efficacy than properly manufactured tablets or capsules. Product identity, botanical authentication, ingredient ratio, extraction method, concentration, storage, and quality control may all influence the finished preparation.

Diet, Activity, and Clinical Context

Weight gain is influenced by energy intake, food quality, physical activity, sleep, medicines, psychological factors, endocrine disorders, and other medical conditions. A short course of Triphala cannot compensate for persistent dietary excess or an untreated cause of weight gain.

Ayurvedic treatment of Sthaulya likewise extends beyond one formulation. Government treatment guidelines place medicines alongside pathya-apathya, activity, assessment of diabetes and thyroid disorders, and treatment selected according to the individual clinical picture. Triphala may therefore be considered only as one component of a broader plan.

Realistic goals include gradual weight reduction, preservation of muscle, improved waist measurement, better food habits, greater daily movement, and management of blood pressure, glucose, lipids, sleep, and associated illnesses. Long-term outcomes matter more than a short change on the weighing scale.

Safety and Who Needs Extra Caution

Most short-term Triphala trials reported few serious treatment-related events, but this does not establish long-term safety at weight-management doses. Gastrointestinal effects, including loose stools or diarrhoea, have been reported. Persistent diarrhoea can contribute to dehydration and is a reason to stop self-treatment and seek professional advice.

Laboratory studies indicate that Triphala extracts can inhibit CYP3A4 and CYP2D6, enzymes involved in the metabolism of many medicines. The clinical importance depends on the product, dose, medicine, and patient, but people taking prescription drugs should have potential interactions reviewed by a healthcare professional. Extra care is appropriate with medicines that have a narrow therapeutic range or are strongly dependent on these pathways.

The cited adult trials did not establish safety during pregnancy, breastfeeding, childhood, or prolonged use in people with serious gastrointestinal, hepatic, renal, or metabolic disease. These groups should not use Triphala for weight loss without guidance from a qualified practitioner. Anyone who develops rash, severe abdominal symptoms, repeated diarrhoea, dizziness, or signs of dehydration should discontinue the product and obtain medical advice.

A Balanced Position

Triphala is an authentic Ayurvedic three-fruit formulation, not merely a modern laxative supplement. Short-term clinical trials and pooled analyses suggest that some Triphala-related preparations may produce modest reductions in body weight or waist circumference. The degree of benefit varies, BMI findings are inconsistent, and the available studies do not establish long-term effectiveness or an optimal product and dose.

Cell, animal, enzyme, and microbiome experiments provide plausible avenues for continued investigation, but they should not be presented as confirmed human mechanisms. Claims of rapid fat burning, guaranteed metabolic improvement, pharmaceutical-equivalent lipid lowering, or substantial weight loss without lifestyle change exceed the available clinical findings.

This article is for educational purposes only. Do not stop or modify prescribed medicines on the basis of this information. Consult a qualified Ayurvedic practitioner and your healthcare provider before using Triphala for weight management, especially if you are pregnant or breastfeeding, have a medical condition, experience chronic diarrhoea, or take prescription medicines.

References

Ayurvedic Herbs for Weight Loss: The 2025 Obesity Trial Results

Dr. Ananya Sharma — Wed, 18 Feb 2026 09:30:00 +0000

Last month, a patient I will call Sunita sat across from me with the kind of frustration I hear often in weight-management consultations: the initial drop after a new diet plan, followed by regain, heaviness, fatigue, and the feeling that the body is resisting every effort.

For patients like this, Ayurveda does not look at weight only as a number on the scale. It looks at Meda Dhatu, Agni, Kapha, food habits, sleep, daily movement, bowel pattern, appetite, stamina, and the person’s constitutional pattern. That is why the 2025 clinical trial on Vyoshadi Guggulu and Vidanga Churna is worth examining carefully: it evaluated an Ayurvedic approach to obesity while also recording Ayurvedic clinical parameters.

The Trial: What They Actually Tested

Sanjay Kumar Giri and colleagues published a prospective, multicentre, open-label, single-arm clinical study in Global Advances in Integrative Medicine and Health in 2025. The trial evaluated the safety and efficacy of two Ayurvedic formulations, Vyoshadi Guggulu and Vidanga Churna, in individuals with obesity.

The intervention used in the trial was:

Vyoshadi Guggulu (VSG): 1 gram three times daily after food with lukewarm water
Vidanga Churna (VDC): 3 grams twice daily after food

The trial recruited 100 participants across two CCRAS centres, the Central Ayurveda Research Institute in Bengaluru and M.S. Regional Ayurveda Research Institute in Jaipur. Eighty-six participants completed the study, and the intervention period lasted 12 weeks, followed by a 2-week follow-up without medication.

What makes the study clinically interesting is that it did not treat obesity as only a body-weight endpoint. Ayurvedic evaluation included Prakriti, Agni, Meda Dhatu, Ahara Shakti, Satmya, Saara, Satva, and Vyayama Shakti. These are not decorative terms in Ayurveda; they shape how a practitioner understands the pattern behind excess Meda and how strongly a person can tolerate diet, exercise, and herbal intervention.

The Numbers That Matter

The trial reported statistically significant improvements in BMI, waist circumference, total serum cholesterol, and LDL cholesterol. Body weight decreased numerically, but that change was not statistically significant, and DEXA scan values did not show a statistically significant change during the study period.

Parameter	Reported change	P-value
BMI	29.99 ± 4.392 to 29.64 ± 3.228	P = 0.016
Waist circumference	100.32 ± 7.810 cm to 97.93 ± 7.600 cm	P = 0.043
Body weight	77.93 ± 11.321 kg to 75.83 ± 10.799 kg	P = 0.113
Total serum cholesterol	176.56 ± 36.590 mg/dL to 164.71 ± 44.653 mg/dL	P = 0.002
LDL cholesterol	Significant reduction	P = 0.033

The practical reading is important: the trial supports a favourable direction in BMI, abdominal measurement, and lipid parameters, but it does not prove major weight loss. It is best read as supportive evidence for a complementary Ayurvedic metabolic approach, not as proof that the formulations alone are a complete obesity treatment.

The safety finding is also clinically meaningful. No adverse drug reactions or adverse events were reported during the study period. At the same time, the study design was open-label and single-arm, so longer, controlled trials are still needed before making broad claims about long-term efficacy and safety.

Why These Herbs? The Ayurvedic Logic

Ayurveda describes obesity under terms such as Sthaulya, Atisthaulya, and Medoroga. In Charaka Samhita, Sutra Sthana Chapter 21, excessive obesity is included among the eight undesirable physical constitutions. Charaka describes causes such as over-nourishment, heavy, sweet, cold, unctuous diet, lack of exercise, daytime sleep, and hereditary tendency, with excess Meda becoming prominent.

Among the bodily types described in Charaka’s Ashtauninditiya chapter, the excessively obese and the excessively lean are given special attention because of their clinical consequences.

In Ayurvedic reasoning, Medoroga is not reduced to overeating alone. A person may have excess Kapha, disturbed Meda Dhatu, obstructed channels, poor daily movement, irregular appetite patterns, unsuitable diet, and impaired tissue-level transformation. A useful protocol must therefore support Agni, reduce Kapha-Meda accumulation, improve bowel and appetite patterns, and include movement appropriate to the person’s strength.

Vyoshadi Guggulu

Vyoshadi Guggulu is a classical polyherbal Guggulu formulation listed in the Ayurvedic Formulary of India and referenced in the trial as standardized according to AFI Part I and API Part II. In the trial, each dose was 1 gram, given as two 500 mg tablets, three times daily after food.

From an Ayurvedic perspective, Vyoshadi Guggulu is used where Kapha, Meda, heaviness, and sluggish metabolic function are central features. The trial article describes it as a formulation used in obesity, joint disorders, and metabolic imbalance, with traditional actions directed toward lipid metabolism, Kapha reduction, and Meda Dhatu regulation.

Vidanga Churna

Vidanga Churna is prepared from Vidanga, identified botanically as Embelia ribes. The trial used Vidanga Churna in a dose of 3 grams twice daily after food and notes that the formulation was prepared according to the Ayurvedic Pharmacopoeia of India.

Classically, Vidanga is especially known for Krimighna action, but it is also used in digestive and metabolic contexts. In this trial, its pairing with Vyoshadi Guggulu reflects an Ayurvedic attempt to address not only stored Meda but also digestion, gut-related disturbance, and Kapha-Meda accumulation.

Shunthi and Haritaki Within the Formulation Logic

The trial article identifies Vyoshadi Guggulu as a polyherbal preparation containing ingredients such as Guggulu, Shunthi, and Haritaki. Shunthi, or dry ginger, is valued in Ayurveda for supporting Agni and clearing heaviness. Haritaki is widely used in classical practice for bowel regulation, Rasayana-oriented support, and the management of accumulated metabolic heaviness when selected appropriately.

The clinical logic is therefore not a random mixture of herbs. Guggulu-centred formulations are traditionally used where scraping, mobilizing, and Kapha-Meda reduction are needed; Shunthi supports digestive fire; Haritaki supports bowel movement and channel cleansing; Vidanga adds digestive and Krimighna-oriented support.

What This Means for Practice

One clinical trial should not be turned into a miracle claim. This trial was not placebo-controlled, not blinded, and not designed to isolate the independent effect of each herb. It also did not show statistically significant body-weight reduction, DEXA improvement, or quality-of-life improvement during the measured period.

What it does provide is a useful clinical signal: when Vyoshadi Guggulu and Vidanga Churna were given in the specified doses for 12 weeks, participants showed significant improvement in BMI, waist circumference, total cholesterol, and LDL cholesterol, with no reported adverse drug reactions or adverse events during the study period.

For an Ayurvedic practitioner, the most useful part is not only the numerical change. It is the integration of Ayurvedic assessment with measurable metabolic outcomes. Prakriti, Ahara Shakti, Satmya, Saara, Satva, and Vyayama Shakti help clarify why two people with the same BMI may need different levels of diet restriction, different exercise intensity, different herbal choices, and different follow-up intervals.

A Practical Framework With Caveats

For a Kapha-Meda-predominant presentation, a practitioner may consider a framework built around warm, light, Kapha-pacifying food, daily movement, correction of daytime sleep, and carefully selected formulations. The trial dose was Vyoshadi Guggulu 1 gram three times daily after food with lukewarm water and Vidanga Churna 3 grams twice daily after food, but this should not be copied as a self-prescription.

Assessment first: Prakriti, Vikriti, Agni, bowel habit, appetite, sleep, waist measurement, lipid profile, blood glucose status, medications, and exercise capacity should be reviewed.
Diet direction: Reduce heavy, oily, cold, excessively sweet foods and favour warm, freshly prepared, lighter meals suited to the person’s strength and digestion.
Movement: Daily exercise is central in Ayurvedic weight management, but the intensity should match Vyayama Shakti and cardiovascular status.
Monitoring: Weight, waist circumference, energy, bowel pattern, lipids, blood glucose markers, liver function, kidney function, and medication interactions should be monitored where relevant.

Important safety note: Guggulu-containing formulations may not be suitable for everyone. People taking prescription medicines, especially thyroid medicines, anticoagulants, cardiovascular medicines, diabetes medicines, or drugs metabolized through CYP pathways, should consult a qualified Ayurvedic practitioner and their healthcare provider before using these formulations. Pregnant or lactating individuals, people with significant liver or kidney disease, and anyone with complex chronic illness should not self-prescribe.

Back to the Patient Who Feels Stuck

For a patient like Sunita, the lesson is not that one pill fixes obesity. The lesson is that Ayurveda gives a framework for understanding why the body may keep storing, why appetite and fatigue may fluctuate, why waist measurement may matter as much as the scale, and why digestion, sleep, movement, and Meda Dhatu must be treated together.

The 2025 trial gives more confidence in a carefully supervised use of Vyoshadi Guggulu and Vidanga Churna as part of an Ayurvedic obesity-management plan. It does not replace individualized assessment, diet, exercise, or medical care. The best use of this evidence is thoughtful integration: classical reasoning, modern monitoring, and a plan tailored to the person rather than the supplement shelf.